1. Preface
1.1. Report Description
1.1.1. Purpose of the Report
1.1.2. Target Audience
1.1.3. Key Offerings
1.2. Market Segmentation
1.3. Research Methodology
1.3.1. Phase I - Secondary Research
1.3.2. Phase II - Primary Research
1.3.3. Phase III - Expert Panel Review
1.3.4. Assumptions
1.3.5. Approach Adopted

2. Executive Summary
2.1. Market Snapshot: Global Ankylosing Spondylitis Market
2.2. Global Ankylosing Spondylitis Market, By Drug, 2023 (US$ Million)
2.3. Global Ankylosing Spondylitis Market, By Distribution Channel, 2023 (US$ Million)
2.4. Global Ankylosing Spondylitis Market, By Geography, 2023 (US$ Million)
2.5. Attractive Investment Proposition by Geography, 2023

3. Ankylosing Spondylitis Market: Competitive Analysis
3.1. Market Positioning of Key Ankylosing Spondylitis Market Vendors
3.2. Strategies Adopted by Ankylosing Spondylitis Market Vendors
3.3. Key Industry Strategies
4. Ankylosing Spondylitis Market: Macro Analysis & Market Dynamics
4.1. Introduction
4.2. Global Ankylosing Spondylitis Market Value, 2022 - 2032, (US$ Million)
4.3. Market Dynamics
4.3.1. Market Drivers
4.3.2. Market Restraints
4.3.3. Key Challenges
4.3.4. Key Opportunities
4.4. Impact Analysis of Drivers and Restraints
4.5. See-Saw Analysis
4.6. Porter's Five Force Model
4.6.1. Supplier Power
4.6.2. Buyer Power
4.6.3. Threat Of Substitutes
4.6.4. Threat Of New Entrants
4.6.5. Competitive Rivalry
4.7. PESTEL Analysis
4.7.1. Political Landscape
4.7.2. Economic Landscape
4.7.3. Technology Landscape
4.7.4. Legal Landscape
4.7.5. Social Landscape

5. Ankylosing Spondylitis Market: By Drug, 2022-2032, USD (Million)
5.1. Market Overview
5.2. Growth & Revenue Analysis: 2023 Versus 2032
5.3. Market Segmentation
5.3.1. Cosentyx
5.3.2. Humira
5.3.3. Simponi
5.3.4. Remicade
5.3.5. Enbrel
5.3.6. Cimzia
5.3.7. Others

6. Ankylosing Spondylitis Market: By Distribution Channel, 2022-2032, USD (Million)
6.1. Market Overview
6.2. Growth & Revenue Analysis: 2023 Versus 2032
6.3. Market Segmentation
6.3.1. Hospital pharmacy
6.3.2. Retail pharmacy
6.3.3. Online pharmacy


7. North America Ankylosing Spondylitis Market, 2022-2032, USD (Million)
7.1. Market Overview
7.2. Ankylosing Spondylitis Market: By Drug, 2022-2032, USD (Million)
7.3. Ankylosing Spondylitis Market: By Distribution Channel, 2022-2032, USD (Million)
7.4.Ankylosing Spondylitis Market: By Region, 2022-2032, USD (Million)
7.4.1.North America
7.4.1.1. U.S.
7.4.1.1.1. Ankylosing Spondylitis Market: By Drug, 2022-2032, USD (Million)
7.4.1.1.2. Ankylosing Spondylitis Market: By Distribution Channel, 2022-2032, USD (Million)
7.4.1.2. Canada
7.4.1.2.1. Ankylosing Spondylitis Market: By Drug, 2022-2032, USD (Million)
7.4.1.2.2. Ankylosing Spondylitis Market: By Distribution Channel, 2022-2032, USD (Million)
7.4.1.3. Rest of North America
7.4.1.3.1. Ankylosing Spondylitis Market: By Drug, 2022-2032, USD (Million)
7.4.1.3.2. Ankylosing Spondylitis Market: By Distribution Channel, 2022-2032, USD (Million)

8. UK and European Union Ankylosing Spondylitis Market, 2022-2032, USD (Million)
8.1. Market Overview
8.2. Ankylosing Spondylitis Market: By Drug, 2022-2032, USD (Million)
8.3. Ankylosing Spondylitis Market: By Distribution Channel, 2022-2032, USD (Million)
8.4.Ankylosing Spondylitis Market: By Region, 2022-2032, USD (Million)
8.4.1.UK and European Union
8.4.1.1. UK
8.4.1.1.1. Ankylosing Spondylitis Market: By Drug, 2022-2032, USD (Million)
8.4.1.1.2. Ankylosing Spondylitis Market: By Distribution Channel, 2022-2032, USD (Million)
8.4.1.2. Germany
8.4.1.2.1. Ankylosing Spondylitis Market: By Drug, 2022-2032, USD (Million)
8.4.1.2.2. Ankylosing Spondylitis Market: By Distribution Channel, 2022-2032, USD (Million)
8.4.1.3. Spain
8.4.1.3.1. Ankylosing Spondylitis Market: By Drug, 2022-2032, USD (Million)
8.4.1.3.2. Ankylosing Spondylitis Market: By Distribution Channel, 2022-2032, USD (Million)
8.4.1.4. Italy
8.4.1.4.1. Ankylosing Spondylitis Market: By Drug, 2022-2032, USD (Million)
8.4.1.4.2. Ankylosing Spondylitis Market: By Distribution Channel, 2022-2032, USD (Million)
8.4.1.5. France
8.4.1.5.1. Ankylosing Spondylitis Market: By Drug, 2022-2032, USD (Million)
8.4.1.5.2. Ankylosing Spondylitis Market: By Distribution Channel, 2022-2032, USD (Million)
8.4.1.6. Rest of Europe
8.4.1.6.1. Ankylosing Spondylitis Market: By Drug, 2022-2032, USD (Million)
8.4.1.6.2. Ankylosing Spondylitis Market: By Distribution Channel, 2022-2032, USD (Million)

9. Asia Pacific Ankylosing Spondylitis Market, 2022-2032, USD (Million)
9.1. Market Overview
9.2. Ankylosing Spondylitis Market: By Drug, 2022-2032, USD (Million)
9.3. Ankylosing Spondylitis Market: By Distribution Channel, 2022-2032, USD (Million)
9.4.Ankylosing Spondylitis Market: By Region, 2022-2032, USD (Million)
9.4.1.Asia Pacific
9.4.1.1. China
9.4.1.1.1. Ankylosing Spondylitis Market: By Drug, 2022-2032, USD (Million)
9.4.1.1.2. Ankylosing Spondylitis Market: By Distribution Channel, 2022-2032, USD (Million)
9.4.1.2. Japan
9.4.1.2.1. Ankylosing Spondylitis Market: By Drug, 2022-2032, USD (Million)
9.4.1.2.2. Ankylosing Spondylitis Market: By Distribution Channel, 2022-2032, USD (Million)
9.4.1.3. India
9.4.1.3.1. Ankylosing Spondylitis Market: By Drug, 2022-2032, USD (Million)
9.4.1.3.2. Ankylosing Spondylitis Market: By Distribution Channel, 2022-2032, USD (Million)
9.4.1.4. Australia
9.4.1.4.1. Ankylosing Spondylitis Market: By Drug, 2022-2032, USD (Million)
9.4.1.4.2. Ankylosing Spondylitis Market: By Distribution Channel, 2022-2032, USD (Million)
9.4.1.5. South Korea
9.4.1.5.1. Ankylosing Spondylitis Market: By Drug, 2022-2032, USD (Million)
9.4.1.5.2. Ankylosing Spondylitis Market: By Distribution Channel, 2022-2032, USD (Million)
9.4.1.6. Rest of Asia Pacific
9.4.1.6.1. Ankylosing Spondylitis Market: By Drug, 2022-2032, USD (Million)
9.4.1.6.2. Ankylosing Spondylitis Market: By Distribution Channel, 2022-2032, USD (Million)

10. Latin America Ankylosing Spondylitis Market, 2022-2032, USD (Million)
10.1. Market Overview
10.2. Ankylosing Spondylitis Market: By Drug, 2022-2032, USD (Million)
10.3. Ankylosing Spondylitis Market: By Distribution Channel, 2022-2032, USD (Million)
10.4.Ankylosing Spondylitis Market: By Region, 2022-2032, USD (Million)
10.4.1.Latin America
10.4.1.1. Brazil
10.4.1.1.1. Ankylosing Spondylitis Market: By Drug, 2022-2032, USD (Million)
10.4.1.1.2. Ankylosing Spondylitis Market: By Distribution Channel, 2022-2032, USD (Million)
10.4.1.2. Mexico
10.4.1.2.1. Ankylosing Spondylitis Market: By Drug, 2022-2032, USD (Million)
10.4.1.2.2. Ankylosing Spondylitis Market: By Distribution Channel, 2022-2032, USD (Million)
10.4.1.3. Rest of Latin America
10.4.1.3.1. Ankylosing Spondylitis Market: By Drug, 2022-2032, USD (Million)
10.4.1.3.2. Ankylosing Spondylitis Market: By Distribution Channel, 2022-2032, USD (Million)

11. Middle East and Africa Ankylosing Spondylitis Market, 2022-2032, USD (Million)
11.1. Market Overview
11.2. Ankylosing Spondylitis Market: By Drug, 2022-2032, USD (Million)
11.3. Ankylosing Spondylitis Market: By Distribution Channel, 2022-2032, USD (Million)
11.4.Ankylosing Spondylitis Market: By Region, 2022-2032, USD (Million)
11.4.1.Middle East and Africa
11.4.1.1. GCC
11.4.1.1.1. Ankylosing Spondylitis Market: By Drug, 2022-2032, USD (Million)
11.4.1.1.2. Ankylosing Spondylitis Market: By Distribution Channel, 2022-2032, USD (Million)
11.4.1.2. Africa
11.4.1.2.1. Ankylosing Spondylitis Market: By Drug, 2022-2032, USD (Million)
11.4.1.2.2. Ankylosing Spondylitis Market: By Distribution Channel, 2022-2032, USD (Million)
11.4.1.3. Rest of Middle East and Africa
11.4.1.3.1. Ankylosing Spondylitis Market: By Drug, 2022-2032, USD (Million)
11.4.1.3.2. Ankylosing Spondylitis Market: By Distribution Channel, 2022-2032, USD (Million)

12. Company Profile
12.1. Novartis
12.1.1. Company Overview
12.1.2. Financial Performance
12.1.3. Product Portfolio
12.1.4. Strategic Initiatives
12.2. AbbVie
12.2.1. Company Overview
12.2.2. Financial Performance
12.2.3. Product Portfolio
12.2.4. Strategic Initiatives
12.3. Janssen
12.3.1. Company Overview
12.3.2. Financial Performance
12.3.3. Product Portfolio
12.3.4. Strategic Initiatives
12.4. Amgen
12.4.1. Company Overview
12.4.2. Financial Performance
12.4.3. Product Portfolio
12.4.4. Strategic Initiatives
12.5. UCB
12.5.1. Company Overview
12.5.2. Financial Performance
12.5.3. Product Portfolio
12.5.4. Strategic Initiatives
12.6. Pfizer, Inc.
12.6.1. Company Overview
12.6.2. Financial Performance
12.6.3. Product Portfolio
12.6.4. Strategic Initiatives
12.7. Eli Lilly and Company
12.7.1. Company Overview
12.7.2. Financial Performance
12.7.3. Product Portfolio
12.7.4. Strategic Initiatives
12.8. Johnson & Johnson Services, Inc.
12.8.1. Company Overview
12.8.2. Financial Performance
12.8.3. Product Portfolio
12.8.4. Strategic Initiatives
12.9. Merck & Co., Inc.
12.9.1. Company Overview
12.9.2. Financial Performance
12.9.3. Product Portfolio
12.9.4. Strategic Initiatives
12.10. Other Notable Players
12.10.1. Company Overview
12.10.2. Financial Performance
12.10.3. Product Portfolio
12.10.4. Strategic Initiatives